Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Terazosin hydrochloride
Drug ID BADD_D02159
Description Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837].
Indications and Usage For the treatment of symptomatic BPH and mild to moderate hypertension.
Marketing Status Prescription; Discontinued
ATC Code G04CA03
DrugBank ID DB01162
KEGG ID D00610
MeSH ID C041226
PubChem ID 44383
TTD Drug ID D0P9RF
NDC Product Code 59746-383; 67544-581; 50090-2371; 71610-510; 50090-2623; 67544-562; 42291-821; 24689-882; 63187-456; 55700-750; 59746-386; 42291-822; 53002-1250; 70518-0074; 67544-564; 49999-227; 71610-478; 50090-0657; 42291-820; 60760-316; 70518-3114; 50090-0659; 24689-855; 63629-2439; 70518-0342; 71610-546; 59746-385; 53002-1726; 59746-384; 50268-766; 66267-389; 68788-9815; 65372-1127; 71610-595; 68788-9817; 53002-1728; 50268-765; 67544-563; 65862-205; 63629-4525; 50090-1559; 63415-0116; 70518-1875; 53002-1727; 24689-961; 24689-792; 66267-325; 71610-503; 71610-594; 63629-5237; 68788-9816; 50268-767; 63187-620; 42291-823; 50268-764
Synonyms Terazosin | Adecur | Apo-Terazosin | Dysalfa | Hytrin | Flotrin | Hytrin BPH | Hytrine | Heitrin | Deflox | Magnurol | Novo-Terazosin | Nu-Terazosin | PMS-Terazosin | terazosin hydrochloride anhydrous | Sutif | Tazusin | Terazoflo | Terazosin AZU | Terazosin Hexal | Terazosin hydrochloride | terazosin, monohydrochloride, dihydrate | Terazosina Alter | Terazosina Kern | Terazosina Qualix | Zayasel | A 45975 | ratio-Terazosin
Chemical Information
Molecular Formula C19H26ClN5O4
CAS Registry Number 63074-08-8
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC.Cl
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Amblyopia06.02.01.001--Not Available
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.002--
Back pain15.03.04.005--
Bronchitis11.01.09.001; 22.07.01.001--
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.003--Not Available
Conjunctivitis06.04.01.002; 11.01.06.012--
Constipation07.02.02.001--
Cough22.02.03.001--
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
Dyspepsia07.01.02.001--
Dyspnoea02.01.03.002; 22.02.01.004--
Epistaxis22.04.03.001; 24.07.01.005--
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.004--
Fatigue08.01.01.002--
Flatulence07.01.04.002--
Gout14.09.01.001; 15.01.06.001--Not Available
Headache17.14.01.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
The 1th Page    1 2 3    Next   Last    Total 3 Pages